Emergent Biosolutions (NYSE:EBS) Upgraded by Wall Street Zen to “Buy” Rating

Emergent Biosolutions (NYSE:EBS) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

A number of other research analysts have also weighed in on EBS. Zacks Research raised Emergent Biosolutions to a “hold” rating in a research note on Friday, October 24th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Emergent Biosolutions in a research note on Wednesday, September 3rd. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Emergent Biosolutions in a research note on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Emergent Biosolutions presently has a consensus rating of “Hold” and a consensus price target of $13.50.

Emergent Biosolutions Trading Down 3.2%

Shares of EBS opened at $12.43 on Friday. The company has a debt-to-equity ratio of 1.25, a current ratio of 5.66 and a quick ratio of 3.00. The firm has a 50 day simple moving average of $8.93 and a 200-day simple moving average of $7.38. Emergent Biosolutions has a 1-year low of $4.02 and a 1-year high of $13.41. The stock has a market cap of $663.35 million, a price-to-earnings ratio of 9.56 and a beta of 2.04.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share for the quarter. The business had revenue of $222.50 million for the quarter. Emergent Biosolutions had a return on equity of 21.43% and a net margin of 9.62%. Emergent Biosolutions has set its FY 2023 guidance at EPS. Equities analysts forecast that Emergent Biosolutions will post -0.63 EPS for the current fiscal year.

Insider Activity

In other news, Director Donald W. Degolyer sold 7,844 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total transaction of $67,850.60. Following the completion of the sale, the director directly owned 137,659 shares of the company’s stock, valued at $1,190,750.35. The trade was a 5.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Coleen Glessner sold 30,608 shares of the business’s stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $10.00, for a total transaction of $306,080.00. Following the sale, the executive vice president directly owned 144,319 shares of the company’s stock, valued at $1,443,190. This represents a 17.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,538 shares of company stock valued at $436,783 in the last ninety days. Company insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Emergent Biosolutions

Several hedge funds and other institutional investors have recently made changes to their positions in EBS. Bank of New York Mellon Corp lifted its holdings in shares of Emergent Biosolutions by 40.4% during the 1st quarter. Bank of New York Mellon Corp now owns 17,003 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 4,894 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in shares of Emergent Biosolutions by 22.4% during the 1st quarter. New York State Common Retirement Fund now owns 375,034 shares of the biopharmaceutical company’s stock valued at $1,823,000 after acquiring an additional 68,748 shares in the last quarter. SBI Securities Co. Ltd. lifted its holdings in shares of Emergent Biosolutions by 95.1% during the 1st quarter. SBI Securities Co. Ltd. now owns 12,951 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 6,313 shares in the last quarter. Morse Asset Management Inc lifted its holdings in shares of Emergent Biosolutions by 18.0% during the 1st quarter. Morse Asset Management Inc now owns 187,464 shares of the biopharmaceutical company’s stock valued at $911,000 after acquiring an additional 28,645 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Emergent Biosolutions during the 1st quarter valued at $462,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.